|
Objective : Using genetic engineering techniques , were constructed with HBV / RNAse H1 and H2 genes in prokaryotic expression vector pGSTag, and transformed into E. coli , induced expression of the target protein , the use of prokaryotic expression product as an antigen , monoclonal antibodies, and fight monoclonal antibody serotypes preliminary analysis identified a basis for clinical application . Methods: In this study, fermentation , the recombinant plasmid pGSTag/HBV/RNAseH1 and H2 were transformed into BL21 (DE3) codon plus (?)-RP, HB101, BL21 (DE3) PlysS, G1727, DH5α, BL21 E. coli . The same time with different media (LB, SOB, SOC, TB, 2YT, M9), the different initial concentration of bacteria ( i.e. OD of 0.2,0.4,0.6,0.8,1.0,1.2 ), different induction times (2.0h, 4.0h, 6.0h), the initial pH (6.0,6.5,7.0,7.5,8.0,8.5) and different concentrations of IPTG induction (0.1,0.3,0.6,1.0,2.0,3.0 mmol / L), respectively, the recombinant protein expression , the recombinant bacteria for the growth of bacteria and the blank curve comparison , cells were collected , the initial purification , bacteria (0.5ml) was washed by centrifugation , analyzed by SDS-PAGE and with FR-200 UV-visible spectrometer , smart view 2001 after day biological electrophoresis image analysis system pGSTag/HBV-RNAseH1 and H2 protein expression , simultaneously Westerblot blot analysis . And
|